Male fertility on TRT — the options nobody told you about

This is one of the most significant gaps in how TRT is often initiated in men of reproductive age.

The biology is not complicated, though its implications are. When you administer exogenous testosterone — in any form, injection, gel, pellet, patch — the hypothalamus detects the elevated testosterone level and reduces its output of GnRH. The pituitary, receiving less GnRH, reduces its output of LH and FSH. LH is the signal that tells Leydig cells in the testes to produce testosterone. FSH is the signal that drives spermatogenesis in the Sertoli cells of the seminiferous tubules. When both signals fall to near zero — as they do on TRT — intratesticular testosterone drops dramatically (it is normally fifty to one hundred times higher inside the testis than in the bloodstream), spermatogenesis stops, and the testes atrophy over weeks to months. A man on TRT is, from a reproductive standpoint, in a state of induced hypogonadotropic hypogonadism. His bloodstream is full of testosterone. His testes are not receiving the signals they need to function.

This is well-established endocrinology. It is also consistently underdiscussed in the clinical encounters where TRT is initiated. The gap matters because the treatment options — and the timeline for any recovery — differ substantially depending on when in the TRT course the fertility question arises.

The first option, and increasingly the standard of care in clinics that take men's reproductive health seriously, is HCG alongside TRT from the start. HCG — human chorionic gonadotropin — is an LH analog. It binds to the same LH receptor on Leydig cells and stimulates intratesticular testosterone production, maintaining the testicular environment that spermatogenesis requires. Men on TRT plus HCG maintain significantly better spermatogenesis and testicular volume than men on TRT alone. HCG in this context is off-label — it is FDA-approved for specific fertility indications, not explicitly as a TRT adjunct — but it is well-established in clinical practice and used routinely in men's health settings where fertility preservation is a concern. The argument for adding it proactively, at or before TRT initiation, is simple: it is much easier to maintain spermatogenesis than to recover it after suppression. For any man on TRT who thinks he might want children in the next several years, this conversation should be happening at the start of treatment, not after the semen analysis returns with azoospermia.

The second option adds FSH to the picture. FSH — either derived as clomiphene-stimulated endogenous FSH or administered as recombinant FSH (rFSH) — is the more direct driver of spermatogenesis. Some men on TRT who have failed to maintain sperm counts with HCG alone, or who are attempting to recover spermatogenesis after a period of TRT without HCG, benefit from the addition of FSH. The combination of HCG plus rFSH is used in men with hypogonadotropic hypogonadism who are attempting fertility, and the same approach can be applied in men with TRT-induced suppression who are actively trying to conceive. This is reproductive endocrinology territory, and it requires specialist management — not because the treatments are dangerous but because the monitoring, the dosing adjustments, and the timeline expectations require specialist experience to navigate correctly.

The third option is TRT discontinuation with a restart protocol. For men who have not used HCG during TRT and are now confronted with azoospermia and a desire for fertility, coming off TRT and attempting to restart endogenous production is the most common clinical path. The tools are SERMs — clomiphene or enclomiphene — which block estrogen feedback at the pituitary and allow LH and FSH to rise, driving endogenous testosterone production. Enclomiphene, the trans-isomer of clomiphene, has been studied specifically for this application and avoids some of the estrogenic side effects of the racemic clomiphene mixture. The protocol typically involves stopping TRT, allowing the exogenous testosterone to clear, and beginning SERM therapy to restart pituitary signaling. HCG may be used in the early phase to support Leydig cell recovery while pituitary signaling restores.

The timeline expectations here deserve honest framing, because this is where the most significant distress arises in clinical practice. Spermatogenesis takes approximately 72 to 74 days from stem cell to mature sperm — roughly two and a half months. Recovery of adequate spermatogenesis after TRT suppression typically takes months, not weeks, and in some cases has taken a year or more even with active restart protocols. Men with longer durations of TRT use, higher testosterone doses, and no HCG co-administration during TRT tend to have longer recovery times. For some men, particularly those with prolonged high-dose exposure, full baseline recovery may not occur — though this appears to be a minority. The uncertainty in the recovery timeline is real and should be communicated honestly.

Sperm banking before TRT initiation is the simplest and most complete solution to all of this, and it is underused. For any man who has not definitively closed the door on having biological children, a semen analysis and cryopreservation before beginning TRT costs relatively little, requires minimal time, and eliminates the fertility anxiety entirely. It is the equivalent of an insurance policy with a very low premium and a potentially very high value. It is remarkable how rarely it is discussed during the TRT initiation conversation.

Kisspeptin-10 represents an emerging area of research interest for HPG axis restart. As the upstream activator of GnRH release, kisspeptin sits at the highest point in the hormonal cascade, and research has suggested that kisspeptin administration can drive LH pulsatility and downstream testosterone in men with hypogonadotropic hypogonadism. Whether kisspeptin-based approaches will prove clinically useful in the post-TRT recovery context — where the axis has been functionally suppressed rather than structurally damaged — is an open question. The research is early. The mechanism is physiologically coherent. It is an area where the science is developing, and specialist guidance on any use is essential.

The man in this situation is not facing an outcome that is irreversible in most cases. He is facing a situation that requires specialist evaluation — specifically, referral to a reproductive endocrinologist or urologist with fertility expertise — and a realistic conversation about timelines, options, and monitoring. The appropriate next step is a semen analysis to characterize the current picture, a hormonal panel to assess where the axis is, and a consultation with a fertility specialist who can construct a protocol matched to the specific clinical situation. General men's health providers can initiate the conversation, but the management of male factor infertility in the TRT context benefits from the experience of a reproductive specialist.

What's most worth saying to any man starting TRT — or considering it — is that the fertility question is not a future problem to address if it arises. It is a present question with present options that are substantially better when addressed before TRT begins than after azoospermia is discovered. HCG co-administration, sperm banking, or the simple decision to use a fertility-preserving protocol from the start: these options exist, they work, and they are almost always better than trying to reverse suppression that was allowed to develop. The conversation should happen in the prescribing appointment, not in the fertility clinic two years later.